Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 3NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial NeoplasmsActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Nov 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05261399Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have...AstraZeneca · CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 6, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanSanofi · Immune ThrombocytopeniaActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03981796A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or...Tesaro, Inc. · NeoplasmsActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 26, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04099251Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaBristol-Myers Squibb · MelanomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Jun 28, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04157348Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.AstraZeneca · Eosinophilic Granulomatous VasculitisActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Aug 10, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02152631A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerEli Lilly and Company · Non Small Cell Lung CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Sep 15, 2017Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02246621A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerEli Lilly and Company · Breast CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 31, 2017Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02411448A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive...Eli Lilly and Company · Metastatic Non-Small Cell Lung CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 23, 2019Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02665065Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaActinium Pharmaceuticals · Acute Myeloid LeukemiaActive, not recruitingATNMLead
- Enrollment
- Locked
- Primary completion
- Jun 2022Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Supernus Pharmaceuticals, Inc. · Attention-Deficit/Hyperactivity DisorderActive, not recruitingSUPNLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT03706365A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerEli Lilly and Company · Prostate CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 2, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04229979Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Sellas Life Sciences Group · Acute Myeloid LeukemiaActive, not recruitingSLSLead
- Enrollment
- Locked
- Primary completion
- Dec 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT04442022A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse...Karyopharm Therapeutics Inc · Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingKPTIQLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen...AbbVie · Myelofibrosis (MF)Active, not recruitingABBVLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04639986Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Gilead Sciences · Metastatic Breast CancerActive, not recruitingGILDLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT04871282A Study of AL102 in Patients With Progressing Desmoid TumorsImmunome, Inc. · DesmoidActive, not recruitingIMNMLead
- Enrollment
- Locked
- Primary completion
- Dec 3, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05257408Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or...Corcept Therapeutics · Ovarian NeoplasmActive, not recruitingCORTLead
- Enrollment
- Locked
- Primary completion
- Mar 31, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05559359A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEli Lilly and Company · Atopic DermatitisActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 14, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05711940Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDCOMPASS Pathways · Treatment Resistant DepressionActive, not recruitingCMPSLead
- Enrollment
- Locked
- Primary completion
- Nov 13, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT06132893A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyBiohaven Therapeutics Ltd. · Focal EpilepsyActive, not recruitingBHVNLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06269705ZILRETTA in Subjects With Shoulder OsteoarthritisPacira Pharmaceuticals, Inc · Glenohumeral OsteoarthritisActive, not recruitingPCRXLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis...AbbVie · Hidradenitis SuppurativaActive, not recruitingABBVLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Mirum Pharmaceuticals, Inc. · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)Active, not recruitingMIRMLead
- Enrollment
- Locked
- Primary completion
- Jul 29, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06662383A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityEli Lilly and Company · ObesityActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Nov 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 78 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.